Getidin

Composition :

Each ml GETIDIN^® Injection contain Ranitidine HCl equivalent with Ranitidine 25 mg

 

Pharmacology :

An histamine H2 receptor antagonist inhibits histamine work competitively on H2 receptors and reduces gastric acid secretion. Levels in serum needed to inhibit 50% stimulation of gastric acid secretion is 36 – 94 mg/ml. These levels last for 6 – 8 hours.

 

Indication :

For hospitalized patients with a pathological hypersecretion or an intractable duodenal ulcer, or as a short-term alternative treatment of oral administration in patients who can not be given oral Ranitidine.

 

Dosage :

Injection i.m. : 50 mg (without dilution) every 6 – 8 hours.

Injection i.v. : intermittent.

• Intermittent bolus :

50 mg (2 ml) every 6 – 8 hours. Dilute 50 mg injection in 0.9% NaCl solution or another suitable solution i.v. injection to a concentration which is is not exceed than 2.5 mg / ml (total volume of 20 ml). Injection speed is not more than 4 ml / min (for 5 minutes).

• Intermittent infusion :

50 mg (2 ml) every 6 – 8 hours. Dilute 50 mg injection in 5% dextrose injection solution or anothe suitable i.v solution to obtain a concentration which it is not axceed than 0.5 mg / ml (total volume of 100 ml). Infusion rate is not more than 5 – 7 ml / min (for 15 – 20 minutes).

• Infus i.v. continuous :

150 mg Ranitidine is diluted in 250 ml of Dextrose or another suitable i.v solution and infused with a speed of 6.25 mg / h for 24 hours. For people with Zollinger Ellison or other hypersecretory, Ranitidine injection should be diluted with 5% dextrose solution or i.v solution. otherwise suitable to obtain a concentration of no more than 2.5 mg / ml. The infusion rate begins 1 mg / kg body weight / hour, and should be adjusted to the patients.

 

Presentation and Registration Number :

GETIDIN^® Injection Box, 5 ampoules @ 2 ml; DKL0908015243A1

 

ON MEDICAL PRESCRIPTION ONLY

 

 

Categorised in:

This post was written by admin